Core Viewpoint - Clover Health Investments, Corp. reported quarterly earnings of $0.03 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.01 per share a year ago [1] - The company posted revenues of $477.62 million for the quarter ended June 2025, which was 1.01% below the Zacks Consensus Estimate, but up from $356.26 million year-over-year [2] Group 1: Earnings Performance - Clover Health surpassed consensus EPS estimates three times over the last four quarters, with a notable surprise of +171.43% in the previous quarter [1] - The current consensus EPS estimate for the upcoming quarter is $0.03, with projected revenues of $463.9 million, and for the current fiscal year, the estimate is $0.11 on $1.89 billion in revenues [7] Group 2: Stock Performance and Outlook - Clover Health shares have declined approximately 8.6% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook and management commentary will be crucial for determining the sustainability of the stock's price movement [3][4] Group 3: Industry Context - Clover Health operates within the Zacks Medical Info Systems industry, which is currently ranked in the top 29% of over 250 Zacks industries [8] - The performance of Clover Health's stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [8]

Company Performance - Inspire Medical Systems reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.22 per share, and up from $0.32 per share a year ago [1] - The earnings surprise for this quarter was +104.55%, following a previous surprise of +143.48% when the company reported earnings of $0.1 per share against an expected loss of $0.23 per share [2] - The company achieved revenues of $217.09 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.95% and increasing from $195.88 million year-over-year [3] Market Outlook - Despite the positive earnings report, Inspire shares have declined approximately 32% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [4] - The future performance of Inspire's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [5][6] - The current consensus EPS estimate for the upcoming quarter is $0.59 on revenues of $239.64 million, and for the current fiscal year, it is $2.26 on revenues of $949.14 million [8] Industry Context - The Medical Info Systems industry, to which Inspire belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [9] - The performance of Inspire's stock may also be influenced by the overall industry outlook, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [9]

Hims & Hers Health, Inc. (HIMS) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.56%. A quarter ago, it was expected that this company would post earnings of $0.12 per share when it actually produced earnings of $0.2, delivering a surprise of +66.67%.Over the last four quarters, the ...

Core Viewpoint - Fulgent Genetics, Inc. reported quarterly earnings of $0.07 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.23 per share, marking an earnings surprise of +130.43% [1] Financial Performance - The company posted revenues of $81.8 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 7.80% and showing an increase from $71.03 million year-over-year [2] - Over the last four quarters, Fulgent Genetics has surpassed consensus EPS estimates four times and topped consensus revenue estimates four times as well [2] Stock Performance - Fulgent Genetics shares have declined approximately 7% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] Future Outlook - The company's earnings outlook will be crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.22 on revenues of $78.25 million, and -$0.62 on revenues of $309.87 million for the current fiscal year [7] Industry Context - The Medical Info Systems industry, to which Fulgent Genetics belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Company Performance - Butterfly Network, Inc. reported a quarterly loss of $0.06 per share, which was better than the Zacks Consensus Estimate of a loss of $0.07, representing an earnings surprise of +14.29% [1] - The company posted revenues of $23.38 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 2%, but showing an increase from $21.49 million year-over-year [2] - Over the last four quarters, Butterfly Network has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Butterfly Network shares have declined approximately 45.2% since the beginning of the year, contrasting with the S&P 500's gain of 7.8% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.07 on revenues of $24.42 million, and for the current fiscal year, it is -$0.27 on revenues of $97.39 million [7] Industry Context - The Medical Info Systems industry, to which Butterfly Network belongs, is currently ranked in the top 23% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Butterfly Network's stock performance [5]

iRhythm Technologies (IRTC) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.61 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +39.62%. A quarter ago, it was expected that this company would post a loss of $0.89 per share when it actually produced a loss of $0.95, delivering a surprise of -6.74%. Over the last four quarters, the company ha ...

Company Performance - Omnicell reported quarterly earnings of $0.45 per share, exceeding the Zacks Consensus Estimate of $0.31 per share, but down from $0.51 per share a year ago, representing an earnings surprise of +45.16% [1] - The company achieved revenues of $290.56 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 4.99% and up from $276.79 million year-over-year [2] - Omnicell has consistently surpassed consensus EPS estimates for the last four quarters [2] Stock Outlook - The stock has underperformed, losing about 33.3% since the beginning of the year, compared to the S&P 500's gain of 8.2% [3] - The company's earnings outlook and estimate revisions will be crucial for future stock performance [4][6] - Current consensus EPS estimate for the upcoming quarter is $0.31 on revenues of $285.69 million, and for the current fiscal year, it is $1.35 on revenues of $1.13 billion [7] Industry Context - The Medical Info Systems industry, to which Omnicell belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5]

Core Insights - Pulmonx Corporation reported a quarterly loss of $0.38 per share, slightly better than the Zacks Consensus Estimate of a loss of $0.40, and compared to a loss of $0.39 per share a year ago, indicating an earnings surprise of +5.00% [1] - The company achieved revenues of $23.86 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.25% and showing an increase from $20.78 million in the same quarter last year [2] - Pulmonx shares have declined approximately 54.5% year-to-date, contrasting with the S&P 500's gain of 8.3% [3] Financial Performance - Over the last four quarters, Pulmonx has exceeded consensus EPS estimates four times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.39 on revenues of $23.49 million, and for the current fiscal year, it is -$1.52 on revenues of $97.19 million [7] Market Outlook - The company's earnings outlook will be crucial for future stock performance, with management's commentary on the earnings call expected to influence investor sentiment [3][4] - The Zacks Rank for Pulmonx is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] Industry Context - The Medical Info Systems industry, to which Pulmonx belongs, is currently ranked in the top 23% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Hims & Hers Health, Inc., is expected to report a quarterly earnings increase of +200% and revenues of $551.84 million, up 74.8% from the previous year [9][10]

Key Takeaways Hims & Hers Health, Inc. (HIMS) is scheduled to report second-quarter 2025 results on Aug. 4, after the closing bell. In the last reported quarter, the company's earnings per share (EPS) of 20 cents topped the Zacks Consensus Estimate by 66.7%. Over the trailing four quarters, its earnings outperformed the Zacks Consensus Estimate on two occasions, missed once and broke even in the other, delivering an earnings surprise of 19.6%, on average. Let's check out the factors that have shaped HIMS' p ...

Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Doximity (DOCS) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revis ...